Table 1—

Effects on kidney function and arterial blood pressure of increasing doses of candesartan in 23 type 2 diabetic patients with nephropathy

ParameterPlaceboCandesarian dose
8 mg16 mg32 mg
Albuminuria (mg/24-h)*700 (486–1,007)470 (270–778)†288 (272–462)†‡332 (176–559)†‡
GFR (ml/min/1.73 m2)84 ± 679 ± 6†78 ± 6†77 ± 6†
θ Albumin (10−6)*163 (101–262)96 (56–166)†85 (48–151)†104 (59–210)†
θ IgG (10−6)*58 (35–95)36 (22–57)†36 (21–63)†39 (22–71)†
θ IgG4 (10−9)*42 (27–64)30 (18–49)†22 (12–39)†34 (19–64)†
Systolic BP (mmHg)
 24-h147 ± 4138 ± 4†138 ± 4†134 ± 4†
 Day153 ± 4143 ± 4†144 ± 4†140 ± 4†
 Night135 ± 4126 ± 4†124 ± 4†122 ± 4†
Diastolic BP (mmHg)
 24-h78 ± 273 ± 2†73 ± 2†71 ± 2†
 Day81 ± 276 ± 2†76 ± 2†74 ± 2†
 Night70 ± 266 ± 2†67 ± 2†65 ± 2†

  • Data means ± SEM.

  • *

    ↵* Geometric mean (95% CI);

  • †

    ↵† P < 0.05 versus placebo;

  • ‡

    ↵‡ P < 0.01 versus 8 mg.